STOK - Stoke Therapeutics Inc
IEX Last Trade
14.57
0.670 4.598%
Share volume: 612,652
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.90
0.67
4.82%
Fundamental analysis
24%
Profitability
25%
Dept financing
7%
Liquidity
75%
Performance
15%
Performance
5 Days
4.00%
1 Month
-0.21%
3 Months
5.59%
6 Months
82.79%
1 Year
153.04%
2 Year
-2.35%
Key data
Stock price
$14.57
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.35 - $17.58
52 WEEK CHANGE
$1.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Edward Kaye
Region: US
Website: https://www.stoketherapeutics.com/
Employees: 113
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.stoketherapeutics.com/
Employees: 113
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.
Recent news